Shares in Adamis Pharmaceuticals (NSDQ:ADMP) soared more than 50% yesterday after it won FDA approval for its generic EpiPen emergency allergy pre-filled syringe, sending shares in competitor Mylan (NSDQ:MYL) down -3%.
For years, Mylan has commanded more than 90% of the market for emergency epinephrine injectors.
Get the full story at our sister site, Drug Delivery Business News.
The post Adamis up, Mylan down on generic EpiPen approval appeared first on MassDevice.